Division of Hematology & Oncology, Department of Medicine.
Department of Pathology.
Blood Adv. 2022 Aug 9;6(15):4403-4407. doi: 10.1182/bloodadvances.2022007809.
• A reduction in hemolysis with voxelotor analog, GBT1118, reduced hemoglobinuria and kidney injury biomarkers in transgenic sickle mice. • Improved chronic hemolysis preserved kidney function and histopathologic and ultrastructural changes in transgenic sickle mice.
• 与 voxelotor 类似物 GBT1118 相比,溶血减少可降低转铁蛋白镰状细胞小鼠的血红蛋白尿和肾脏损伤生物标志物。 • 改善慢性溶血可维持转铁蛋白镰状细胞小鼠的肾功能以及组织病理学和超微结构改变。